In the News
March 2013: Celleration Reaches Key Milestone of 1 Million MIST Therapy Treatments
(Eden Prairie, MN) – March 13, 2013 – Celleration, Inc., a privately-held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies to treat wounds, announced today that over 1 million MIST® Therapy treatments have been performed in the United States and U.K. benefiting more than 65,000 patients. Read Press Release
September 2012: Celleration Launches New Applicator Design with Improved Ease of Use
(Eden Prairie, MN) – September 24, 2012 – Celleration, Inc., a privately-held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announces the launch of its new MIST® 360o Applicator. The new applicator design provides increased flexibility to access even the most difficult to reach wounds while allowing larger wounds to be treated more easily. Read Press Release
May 2012: Celleration Announces First Enrollment in IN-BALANCE VLU Randomized-Control Trial
(Eden Prairie, MN) – May 2, 2012 – Celleration, Inc., a privately-held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announced the first patient enrollment in IN-BALANCE VLU (Inflammation, Bacteria, & Angiogenesis effects in Launching Venous Leg Ulcer healing: A Clinical Evaluation). IN-BALANCE VLU is designed to expand on the vast body of evidence on MIST Therapy® supporting the clinical and economic benefits of the FDA cleared wound healing therapy.
Read Press Release
March 2011: Celleration Announces Release of Award-Winning Clinical Results at National Pressure Ulcer Advisory Panel (NPUAP)
(Eden Prairie, MN) –March 3, 2011 – Celleration, Inc. announced the release of award-winning clinical results at the 2011 National Pressure Ulcer Advisory Panel (NPUAP) Biannual meeting in Las Vegas using MIST® Ultrasound Healing Therapy. The clinical results using MIST Therapy to treat deep tissue injuries(DTI), a form of pressure ulcer or bed sore, were so compelling that the poster was awarded NPUAP’s top award for contribution to the field of pressure ulcer research. Read Press Release
January 2011: Celleration Announces Close of $8 Million Series E Financing
(Eden Prairie, MN) – January 11, 2011 – Celleration, Inc. announced the closing of an $8 million Series E round of equity financing. All of the Company’s existing institutional investors participated in this round in addition to Sightline Healthcare Opportunity Fund who participated as a new investor. Read Full Story
November 2009: The Celleration Story in FORBES Magazine!
National publications recognize that Celleration is something special and MIST Therapy is the only stimulating therapeutic technology clinically proven across the wound healing matrix to painlessly accelerate the natural wound healing process and reduce bioburden. Read Full Story
July 2009: Celleration Appoints Mark T. Wagner President and Chief Executive Officer
(Eden Prairie, MN) – July 1, 2009 – Celleration, Inc., developer of the patented MIST Therapy® System, an innovative device that uses ultrasound to heal wounds, has named Mark T. Wagner as president and chief executive officer and member of Celleration’s board of directors. Mr. Wagner brings a successful track record of developing and commercializing medical devices spanning 30 years to the Celleration team. Read Full Story